In re Xyrem (Sodium Oxybate) Antitrust Litigation

Track this case

Case overview

Case Number:

3:20-md-02966

See also:

Court:

California Northern

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Richard Seeborg

Firms

Companies

Sectors & Industries:

  1. May 08, 2025

    Hikma Cuts $50M Deal To End Antitrust Claims In Xyrem MDL

    A certified class of Xyrem buyers in 36 states have asked a California federal judge to preliminarily approve Hikma Pharmaceuticals PLC's $50 million deal to resolve antitrust claims accusing Hikma of colluding with rival Jazz Pharmaceuticals to block generic rivals from competing with Jazz's narcolepsy drug.

  2. April 08, 2025

    Jazz Agrees To Pay $145M To Settle Xyrem Antitrust Fight

    Jazz Pharmaceuticals has agreed to pay $145 million to resolve antitrust litigation accusing it of working with its rival Hikma Pharmaceuticals to stave off generic competitors to Jazz's narcolepsy drug Xyrem, the Ireland-based pharmaceutical company revealed Tuesday.

  3. March 17, 2025

    Jazz Inks Insurer Class Deal As Xyrem Antitrust Trial Nears

    Jazz Pharmaceuticals and a certified insurer class told a California federal judge Monday that they have reached a settlement-in-principle in antitrust litigation accusing Jazz of working with pharma rival Hikma to block generic competitors to Jazz's narcolepsy drug, while two opt-out insurer plaintiffs and defendant Hikma have not reached any deals ahead of a May trial.

  4. August 28, 2024

    Jazz, Hikma Must Face Bulk Of Xyrem Antitrust Suit

    Jazz Pharmaceuticals and Hikma Pharmaceuticals appear bound for trial against most solo insurer and class action antitrust claims over alleged efforts to block generic competitors to Jazz's Xyrem narcolepsy drug, under a newly unsealed California federal court order largely rejecting competing motions for summary judgment.

  5. July 19, 2024

    Jazz Says Narcolepsy Drug Charge MDL Should Be Tossed

    Jazz Pharmaceuticals urged a California federal judge to toss claims from insurers and consumers pursuing multidistrict litigation accusing the drugmaker of staving off generic competition to its blockbuster narcolepsy medicine Xyrem through antitrust conduct and deals with other drugmakers, saying the company engaged in "permissible competition."

  6. November 16, 2023

    Illinois Seeks To Rejoin Narcolepsy Drug Overcharge Suit

    Illinois is looking for a way back into an ongoing class action against Jazz Pharmaceuticals, telling the California federal judge presiding over the multidistrict case that another judge's order excluding Illinois insurers who reimbursed patients for the price of narcolepsy drug Xyrem should be reversed.

  7. May 16, 2023

    Jazz Ducks BCBS Claims But Not Xyrem Class Cert.

    A California federal judge granted class certification Friday to insurers and consumers pursuing multidistrict litigation accusing Jazz Pharmaceuticals of staving off generic competition to its blockbuster narcolepsy drug Xyrem through a web of anti-competitive conduct and deals with other drugmakers, even as he nixed Blue Cross Blue Shield claims.